Slingshot Insights

Catalyst

Slingshot members are tracking this event:

Bellicum Pharma (BLCM) expects to begin Phase 1 trial of BPX-701 in mid 2016 for Refractory or Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes

Source Link:: http://seekingalpha.com/article/3958395-bellicum-pharmaceuticals-blcm-ceo-tom-farrell-q4-2015-results-earnings-call-transcript?part=single

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

BLCM

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details Update on Nov 9 2016: "In the coming weeks, we expect to initiate the Phase 1 clinical trials of our BPX-601 GoCAR-T and BPX-701 TCR product candidates."

http://ir.bellicum.c...

Additional Relevant Details BPX-701 is a high affinity T cell receptor or TCR product candidate incorporating BLCM's CaspaCID safety switch and is designed to target malignant cells expressing the preferentially-expressed antigen in melanoma or PRAME

http://seekingalpha....

Additional Relevant Details
With its BPX-701 IND allowed by the FDA, the Company is preparing for initiation of BP-011, a Phase 1 clinical trial with its high-affinity T cell receptor (TCR) product candidate.

http://ir.bellicum.c...

Additional Relevant Details "We are preparing for initiation of a Phase 1 clinical trial, BP-011, with our high-affinity T cell receptor (TCR) product candidate BPX-701"

http://www.bellicum....

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Aug 08, 2016

Occurred Source:

http://ir.bellicum.com/phoenix.zhtml?c=253830&p=irol-newsArticle&ID=2193851

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords Phase 1 Trial, Bpx-701, Acute Myeloid Leukemia, Myelodysplastic Syndrome, T Cell Receptor, Tcr Product